WHO places a new drug in the priority drugs list for treating multi-drug resistant TB

Bedaquiline, a Group C drug has been recently placed by World Health Organisation (WHO) under Group A belonging to the priority drugs list required for treating multi-drug resistant tuberculosis.

By: Sreemoyee Chatterjee | | Published: August 20, 2018 11:02 am

Steps are taken by forthcoming first-ever UN High Level Meeting (UNHLM) to #endTB. © Shutterstock

A new drug has been added to the list of priority drugs used for treating those suffering from multi drug resistant tuberculosis (MDR-TB), thanks to World Health Organisation (WHO) for placing bedaquiline along with levofloxacin/moxifloxacin and linezolid in Group A reserved for prioritised medicines. Till now, bedaquiline was placed under Group C which belonged to drugs used when patients become resistant to Group A and Group B drugs, according to the earlier guidelines. Also Read - Obesity, alcohol consumption can lower effectiveness of Covid-19 vaccines

WHO has also warned on safety issues and effectiveness of using bedaquiline on MDR-TB patients for over 6 months as it has not found any evidence yet. Also, WHO has highlighted that patients should restrict the use of linezoid, another efficient drug for MDR-TB due to its severe side effects that can cause temporary or permanent loss of hearing. Also Read - Green Mediterranean diet could benefit people with non-alcoholic fatty liver disease

According to media reports, WHO does not any more recommend the use of kanamycin and capreomycin on TB patients because of increasing risk of treatment failure and relapse related to their use. It has suggested that the countries should no more use kanamycin and wait for its stock to get exhausted but immediately replace it with a comparably less harmful drug – amikacin for short duration. This is because of kanamycin’s ototoxic side effect, eventually resulting in hearing loss. According to WHO, the position of another drug, delamanid will be re-assessed once it receives and reviews individual patient data from the concerned trial. Also Read - Eluru-like mysterious illness emerges in Andhra Pradesh's Pulla village

With US based Johnson and Johnson’s (J&J) Janssen holding the patents for producing bedaquiline at present till 2023, the drug is being imported from the same company and administered to around 1,000 patients in India under the conditional access programme of the government. According to the central government data, over 2,000 patients need this drug. The experts, however, say about 20,000 patients suffering from TB actually require the drug in India.

Image Source: Shutterstock

Published : August 20, 2018 11:02 am

Read Disclaimer

Brain is capable of ignoring bias and make rational calls, says study

Sex and prostate cancer: How are the two connected?

About The health Site

TheHealthSite.com is India's largest health site with more than 40 lakh unique visitors per month. We focus on fitness, beauty, health, pregnancy and more.

Most popular health and wellness website in India in 2012 at the Website of the year awards.

health@corp.india.com

+91 – 22 – 6697 1234

91 – 22 – 2490 0302.

ZEE ENTERTAINMENT ENTERPRISES LTD, 18th floor, A-Wing, Marathon Futurex, N. M. Joshi Marg, Lower Parel, Mumbai, Maharashtra 400013.

We respect your privacy

Brain is capable of ignoring bias and make rational calls, says study

Sex and prostate cancer: How are the two connected?

About The health Site

Useful Links